The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MDS 2021 | MDS: managing HMA failure
Hypomethylating agents (HMA), such as azacitidine and decitabine are standard of care for myelodysplastic syndromes (MDS). However, there remain few options for patients who fail HMAs, which indeed a great many do. Valeria Santini, MD, University of Florence, Florence, Italy, discusses rescue strategies for this patient population. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.
